- Home
- ANGX vs PCRX Comparison
ANGX vs PCRX Comparison
Compare ANGX & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANGX | PCRX |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 989.8M | 1.1B |
| IPO Year | 2021 | 2010 |
Fundamental Metrics
Financial Performance| Metric | ANGX | PCRX |
|---|---|---|
| Price | $4.88 | $25.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $9.75 | ★ $30.25 |
| AVG Volume (30 Days) | ★ 1.8M | 432.8K |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | N/A | ★ 0.19 |
| Revenue | $321,558,306.00 | ★ $541,533,000.00 |
| Revenue This Year | $46.23 | $6.78 |
| Revenue Next Year | $25.81 | $8.54 |
| P/E Ratio | ★ N/A | $129.63 |
| Revenue Growth | ★ 233.16 | 26.04 |
| 52 Week Low | $2.05 | $18.80 |
| 52 Week High | $9.85 | $27.66 |
Technical Indicators
Market Signals| Indicator | ANGX | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 50.49 | 46.57 |
| Support Level | $3.90 | $24.61 |
| Resistance Level | $5.58 | $27.05 |
| Average True Range (ATR) | 0.34 | 0.75 |
| MACD | -0.05 | -0.10 |
| Stochastic Oscillator | 27.20 | 33.33 |
Price Performance
Historical ComparisonAbout ANGX Angel Studios Inc.
Angel Studios Inc is an entertainment company known for crowd-funded films and television projects. It enables creators to share projects and engage audiences directly. The platform allows fans to invest in and promote productions, fostering a community-driven approach to content creation.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.